Global Viral Lower Respiratory Disease Episodes, Hospitalisations, and Clinical Outcomes by Aetiology, 2010–2021
Ekaterina Maslova, Catherine W. Gillespie(Institute for Health Metrics and Evaluation), Pratik Sinha(University of California, San Francisco), Maja Pasovic(Institute for Health Metrics and Evaluation), Samuel B Ewald, Malin Fagerås(AstraZeneca (Brazil)), Quinn Rafferty(Institute for Health Metrics and Evaluation), Jiali Lei(Institute for Health Metrics and Evaluation), Chengbin Wang(AstraZeneca (Singapore)), Darwin Del Castillo(Universidad Científica del Sur), Charlotte Lupton(AstraZeneca (South Korea)), Yao Qiao(AstraZeneca (South Korea)), Jam Suba(University of Washington)
Cited by 0
Related Papers
Global, regional, and national burden of osteoarthritis, 1990–2020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021
|The Lancet Rheumatology|2023|1.7k
Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis
|The Lancet|2022|319
Latent Class Analysis Reveals COVID-19–related Acute Respiratory Distress Syndrome Subgroups with Differential Responses to Corticosteroids
|American Journal of Respiratory and Critical Care Medicine|2021|295
Short-Acting Beta-2-Agonist Exposure and Severe Asthma Exacerbations: SABINA Findings From Europe and North America
|The Journal of Allergy and Clinical Immunology In Practice|2022|79